News
Astellas inks license agreement with Evopoint Biosciences for XNW27011, a novel clinical-stage ADC targeting CLDN18.2 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback